1
Am J Gastroenterol https://doi.org/10.1038/s41395-018- To the Editor We read the article "Higher rate of Barrett's detection in the first year after successful endoscopic therapy: metaanalysis" with great interest [1] . Sawas et al. [1] found that detection rate of intestinal metaplasia (IM) and dysplasia after successful endoscopic eradication therapy (EET) of Barrett's esophagus (BE) was significantly higher within the first year of surveillance compared to the surveillance years that followed. EET as the first-line treatment for BE with dysplasia is highly effective if dysplasia or early cancer is found [2] . However, as the authors mentioned that current surveillance intervals after complete remission of IM (CRIM) were based on expert opinion, which made the detection rate of IM, and dysplasia after successful EET of BE quite unstable. Therefore, the author's findings have great reference value for judging the surveillance intervals after achieving CRIM with endoscopic therapy. We conducted a cumulative meta-analysis according to the (2015) Small (2015) Phoa (2016) Cameron (2016) Komanduri (2017) Guthikonda (2017) Cotton (2017) Gopalakrishnan (2017 (2011) Gupta (2013) Dulai (2013) Korst (2013) Strauss (2014) Conio (2014) Konda (2014) Johnson (2015) Small (2015) Phoa (2016) Cameron (2016) Komanduri (2017) Guthikonda (2017) Cotton (2017) Gopalakrishnan (2017) Belghazi ( data provided by the authors to further support the authors' conclusions. The cumulative meta-analysis is used to determine the point where further similar studies are unlikely to change the confirmed conclusions [3] . In our cumulative meta-analysis, studies were added one at a time according to the order of published year, and the aggregate effect estimate was recalculated after addition of each study. Our cumulative meta-analysis showed that IM detection rate in the first year was not significantly higher compared to all the subsequent years after until adding a 2017 study by Cotton et al. [4] (RR = 1.52, 95% confidence interval (CI): 1.11-2.08, Fig. 1a) , and thereafter, the results remained stable. Figure 1b showed a forest plot for the cumulative meta-analysis of dysplasia detection rate after achieving CRIM between the first year and the subsequent years. A statistically significant difference was first achieved by adding a 2014 study by Conio et al. [5] (RR = 2.44, 95% CI: 1.02-5.83). Thereafter, seven more studies published between the years 2014 and 2017 made the difference not statistically significant (RR = 1.52, 95% CI: 0.96-2.41), while an essential change occurred when the study by Cotton et al. [4] published in 2017 was added (RR = 1.84, 95% CI: 1.22-2.79), and thereafter, this result that dysplasia detection rate was significantly higher in the first year compared to the subsequent years has remained stable after adding three studies published in 2017 and 2018 (RR = 1.90, 95% CI: 1.31-2.76). Regardless of which study was added, the difference in high-grade dysplasia (HGD)/ esophageal adenocarcinoma (EAC) detection rate between the first year and all the subsequent years remained not statistically significant (data not shown).
The results of cumulative meta-analysis can help researchers justify additional studies or realize the need to reorient their research [6] . Our cumulative meta-analysis confirmed again that IM and dysplasia detection rate after achieving CRIM in the first year was significantly higher compared to all the subsequent years after. Relevant studies might not be needed for supporting these results. However, the conclusion that the difference in HGD/EAC detection rate between the first year and all the subsequent years not statistically significant still requires a lot of research to further confirm.
